128 related articles for article (PubMed ID: 6622515)
1. Differential affinity of dopaminergic agonists and antagonists for D1 and D2 dopamine receptors in rat striatum.
Carboni E; Memo M; Spano PF
Pharmacol Res Commun; 1983 Jul; 15(7):697-706. PubMed ID: 6622515
[TBL] [Abstract][Full Text] [Related]
2. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
Urwyler S; Markstein R
J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868
[TBL] [Abstract][Full Text] [Related]
3. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
4. Distinct target size of dopamine D-1 and D-2 receptors in rat striatum.
Nielsen M; Klimek V; Hyttel J
Life Sci; 1984 Jul; 35(3):325-32. PubMed ID: 6235424
[TBL] [Abstract][Full Text] [Related]
5. Autoradiographic identification of D1 dopamine receptors labelled with [3H]dopamine: distribution, regulation and relationship to coupling.
Hervé D; Trovero F; Blanc G; Glowinski J; Tassin JP
Neuroscience; 1992; 46(3):687-700. PubMed ID: 1532052
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury.
Neve KA; Altar CA; Wong CA; Marshall JF
Brain Res; 1984 Jun; 302(1):9-18. PubMed ID: 6428705
[TBL] [Abstract][Full Text] [Related]
7. Quantification of in vivo spiperone binding in the rat striatum after lesions produced by kainate or decortication.
Van der Werf JF; Van het Schip F; Sebens JB; Korf J
Eur J Pharmacol; 1984 Jul; 102(3-4):387-99. PubMed ID: 6436037
[TBL] [Abstract][Full Text] [Related]
8. Binding of 3H-spiperone and 3H-(-)-sulpiride to dopamine D2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands.
Urwyler S; Coward D
Naunyn Schmiedebergs Arch Pharmacol; 1987 Feb; 335(2):115-22. PubMed ID: 2951601
[TBL] [Abstract][Full Text] [Related]
9. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
Leff SE; Creese I
Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
[TBL] [Abstract][Full Text] [Related]
10. Differential affinities of molindone, metoclopramide and domperidone for classes of [3H]spiroperidol binding sites in rat striatum: evidence for pharmacologically distinct classes of receptors.
Rosenfeld MR; Dvorkin B; Klein PN; Makman MH
Brain Res; 1982 Mar; 235(1):205-11. PubMed ID: 6145486
[TBL] [Abstract][Full Text] [Related]
11. Postnatal development of striatal dopamine function. II. Effects of neonatal 6-hydroxydopamine treatments on D1 and D2 receptors, adenylate cyclase activity and presynaptic dopamine function.
Broaddus WC; Bennett JP
Brain Res Dev Brain Res; 1990 Mar; 52(1-2):273-7. PubMed ID: 2110042
[TBL] [Abstract][Full Text] [Related]
12. Aging process affects a single class of dopamine receptors.
Memo M; Lucchi L; Spano PF; Trabucchi M
Brain Res; 1980 Dec; 202(2):488-92. PubMed ID: 7437912
[TBL] [Abstract][Full Text] [Related]
13. Postnatal development of striatal dopamine function. I. An examination of D1 and D2 receptors, adenylate cyclase regulation and presynaptic dopamine markers.
Broaddus WC; Bennett JP
Brain Res Dev Brain Res; 1990 Mar; 52(1-2):265-71. PubMed ID: 2331795
[TBL] [Abstract][Full Text] [Related]
14. Effect of buflomedil (4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxy phenyl)-1-butanone hydrochloride) on the function of striatal dopaminergic neurons.
Koda H; Hashimoto T; Kuriyama K
Jpn J Pharmacol; 1989 Feb; 49(2):215-23. PubMed ID: 2659861
[TBL] [Abstract][Full Text] [Related]
15. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
Gundlach AL; Krstich M; Beart PM
Brain Res; 1983 Nov; 278(1-2):155-63. PubMed ID: 6227373
[TBL] [Abstract][Full Text] [Related]
16. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study.
Savasta M; Mennicken F; Chritin M; Abrous DN; Feuerstein C; Le Moal M; Herman JP
Neuroscience; 1992; 46(3):729-38. PubMed ID: 1532053
[TBL] [Abstract][Full Text] [Related]
17. Differential anatomical location of [3H]-N,n-propylnorapomorphine and [3H]-spiperone binding sites in the striatum and substantia nigra of the rat.
Hall MD; Jenner P; Kelly E; Marsden CD
Br J Pharmacol; 1983 Jun; 79(2):599-610. PubMed ID: 6418246
[TBL] [Abstract][Full Text] [Related]
18. Magnesium ions reveal nanomolar potency of dopamine at [3H]spiperone labelled D-2 receptors in rat corpus striatum.
De Vries DJ; Beart PM
Eur J Pharmacol; 1985 Mar; 109(3):417-9. PubMed ID: 3157589
[TBL] [Abstract][Full Text] [Related]
19. Selective labelling of dopamine (D2) receptors in rat striatum by [3H]domperidone but not by [3H]spiperone.
Lazareno S; Nahorski SR
Eur J Pharmacol; 1982 Jul; 81(2):273-85. PubMed ID: 7117377
[TBL] [Abstract][Full Text] [Related]
20. Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase.
Filloux F; Dawson TM; Wamsley JK
Brain Res Bull; 1988 Apr; 20(4):447-59. PubMed ID: 3135077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
